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Abstract
Background: Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli O157:H7 has been
widely known as a common cause of acute renal failure in children. There are only a few reports of sporadic Shiga
toxin-producing Escherichia coli-hemolytic uremic syndrome in adults in the USA. Analyses from the 2011 outbreak
of hemolytic uremic syndrome associated with Escherichia coli O104:H4 reported that mortality rates are highest in
those patients with age >60-years old. Therefore, recognizing Shiga toxin-producing Escherichia coli-hemolytic
uremic syndrome in older people can help early introduction of the appropriate therapy.
Case presentation: We describe an 86-year-old Caucasian woman, initially treated as suspected thrombotic
thrombocytopenic purpura, with worsening neurological and renal functions despite plasmapheresis (plasma
exchange). A subsequent normal ADAMTS13 activity level and positive stool sample for Escherichia coli O157:H7
confirmed the diagnosis of Shiga toxin-associated hemolytic uremic syndrome. We shifted our management
towards aggressive supportive care. Despite conventional treatment, hemolytic uremic syndrome unfortunately led
to her death.
Conclusions: Our case demonstrates the importance of recognizing Shiga toxin-producing Escherichia
coli-hemolytic uremic syndrome as an etiology of microangiopathic hemolytic anemia in older people. According
to the current literature, supportive care is the best approach for Shiga toxin-producing Escherichia coli-hemolytic
uremic syndrome. Therapies such as plasma exchange and eculizumab (a complement inhibitor) are not shown to
be effective in Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome. There is a dire need to continue
research to find better treatment options in this disease entity with a high mortality, particularly in older people.
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Background
Microangiopathic hemolytic anemia (MAHA) results in
erythrocyte fragmentation, elevated lactate dehydrogenase
(LDH) levels, and microvascular occlusion. MAHA with
normal ADAMTS13 activity level consists of a spectrum
of disorders that includes hemolytic uremic syndrome
(HUS) [1]. HUS can be further categorized into two differ-
ent subsets: classical or typical HUS associated with Shiga
toxin-producing Escherichia coli (STEC) or invasive
pneumococcal infection, and atypical HUS (aHUS) that is
not related to STEC and is driven by complement activa-
tion and dysregulation.
HUS associated with E. Coli O157:H7 has been widely
recognized as one of the main causes of acute renal fail-
ure in children. Supportive care and dialysis have been
previously known as the mainstream therapy in STEC-
HUS in children. However, there are not many cases of
STEC-HUS reported in adults worldwide. The report of
an outbreak of HUS associated with STEC O104:H4 in
Germany in 2011 showed the highest rate of mortality in
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adults >60-years old [2]. The rarity with which this ill-
ness is encountered in adults often delays diagnosis and
limits treatment options for this illness.
In this case report, we demonstrate a case of an 86-year-
old woman affected by STEC-HUS which is an illness
more common in children. Recognizing HUS in older
people and differentiating it from other MAHA entities
can help early diagnosis and treatment.
Case presentation
An 86-year-old Caucasian woman was transferred to our
medical intensive care unit from another medical facility to
provide a higher level of care for thrombotic microangiopa-
thy and acute renal failure. She presented to an emergency
department with an acute onset of abdominal pain and
bright red blood per rectum. She reportedly had some
breathing difficulty. A computed tomography (CT) of her
abdomen had shown nonspecific findings suggestive of col-
itis and therapy had been started with levofloxacin and
metronidazole. Urine studies did not have features of urin-
ary tract infection. She was intubated electively at the other
hospital due to altered mental status and need for supple-
mental oxygen prior to her transfer. Also of note, her family
reported that she had some difficulties with her speech; this
was in the form of difficulties with word-finding alongside
slurring of speech. She had no other neurological deficits at
that time. A diagnosis of MAHA with a suspicion for
thrombotic thrombocytopenic purpura (TTP) was made
and she was transferred to our hospital for a higher level of
medical care. On her arrival at our institution, she contin-
ued to receive metronidazole, cefepime, and tigecycline.
She had medical comorbidities of essential hypertension,
hyperlipidemia, and hypothyroidism. She had no reported
history of infectious, autoimmune, or hematologic diseases.
On physical examination, remarkable skin findings of pur-
pura and ecchymoses were noted. She was intubated and
coarse breath sounds were appreciated on examination.
The laboratory data revealed an elevated creatinine,
markedly elevated serum LDH, and markedly reduced
haptoglobin levels. Her serum ferritin was 739.8 ng/mL,
transferrin saturation was 42 %; her cobalamin and folate
were within normal limits. A peripheral blood smear (Fig. 1)
showed thrombocytopenia and features of MAHA (Table 1).
We approached the case as MAHA with a high sus-
picion for TTP. However, STEC-HUS was also high in
our differential diagnosis since she initially had bloody
diarrhea. We decided to start plasma exchange (PLEX)
alongside methylprednisolone 1 mg/kg twice daily
while awaiting ADAMTS13 activity and Shiga-toxin
assays. She also underwent hemodialysis for acute
renal failure. After an initial improvement in hemolysis
and thrombocytopenia, her laboratory and clinical pa-
rameters of MAHA failed to improve in subsequent
days of hospitalization. Three days later, ADAMTS13
activity level was reported as 92 % (normal range, 68
to 163 % activity); her stool sample was positive for
STEC and a culture was positive for E. coli O157:H7.
These findings were consistent with a diagnosis of
STEC-HUS; therefore we recommended discontinu-
ation of corticosteroid and plasmapheresis. We had a
lengthy discussion with the family members regarding
the limited efficacy of available treatment options.
Given her worsening clinical condition, the family de-
cided on palliative measures; she died on her fourth
day of hospitalization at our institution.
Discussion
STEC-HUS is a life-threatening illness that is character-
ized by MAHA, thrombocytopenia, and acute renal in-
jury which affects 6 to 9 % of STEC infections [3]. Less
commonly, neurological involvement is also found to be
associated with STEC-HUS infection. The pathophysi-
ology behind STEC causing organ damage is through
vasculoendothelial injury. Shiga toxin (Stx) is released by
these toxic strains of bacteria into the gastrointestinal
tract system and gets absorbed into the systemic circula-
tion where it binds to globotriaosylceramide (Gb3) on
the surface of vascular endothelial cells in different tar-
get organs, particularly the kidney and brain. Stx injures
endothelial cells by inhibiting protein synthesis, inducing
broad inflammatory response, and releasing cytokines
and chemokines. This endothelial cell injury increases
risk of thrombosis and organ damage [4]. Shiga toxin
also activates the alternative pathway of complement
system by binding to factor H proteins, known as com-
plement control proteins, and reducing their cell surface
activity [5]. Furthermore, Stahl et al. studied the effects
of STEC on complement system and illustrated the in-
creased binding of microparticles from platelets and
Fig. 1 Peripheral blood smear exhibiting features of
microangiopathy and marked thrombocytopenia. Severe anemia
with schistocytes (black solid arrow), reticulocytosis (white arrow), and
spherocytes (empty arrow)
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monocytes in the plasma of patients with HUS to C3
and C9 complement factors, thereby activating them,
during the acute phase of the illness causing inflamma-
tory and prothrombotic changes in different organs [6].
The usual presentation of STEC-HUS starts with a pro-
dromal illness with abdominal pain, vomiting, and diarrhea
that precedes MAHA, thrombocytopenia, and acute kidney
injury (AKI) by 5 to 10 days. MAHA is characterized by
hemoglobin levels usually less than 8 g/dL, negative
Coombs test, elevated serum indirect bilirubin concentra-
tion, elevated serum LDH level, decreased serum haptoglo-
bin concentration and a peripheral blood smear showing a
large number of schistocytes and reticulocytes and nucle-
ated red blood cells. Thrombocytopenia is characterized by
a platelet count below 150,000/mm3. AKI is much harder
to define since the severity of renal involvement in STEC-
HUS varies from hematuria and proteinuria to develop-
ment of severe AKI and oliguria requiring dialysis. Studies
have shown that about 50 % of patients with HUS require
dialysis during the acute phase [5, 7]. There can be add-
itional organ involvements in HUS, with 20 to 25 % of
patients with HUS developing life-threatening neurological
involvement with severe neurological symptoms such as
lethargy, apnea, coma, seizures, cortical blindness, and
hemiparesis [3]. Brain magnetic resonance imaging in
patients with severe neurological involvement revealed ab-
normal findings in the basal ganglia, thalami, and brainstem
[8]. Severe central nervous system (CNS) involvement has
been shown to be associated with higher mortality [4].
Although we are more familiar with the occurrence
of the disease in children, there have now been a few
studies recognizing the occurrence of STEC-HUS in
adults. Gould et al. analyzed data from Foodborne Dis-
eases Active Surveillance Network (FoodNet) population-
based surveillance for E. Coli O157:H7 infection and for
HUS from the years 2000 to 2006 in eight different states
in the USA to further explore demographic risk factors for
the development of STEC-HUS and to evaluate mortality
rates associated with STEC-HUS by age. From their data
analyses, they reported that young females of <5-years old
had the highest risk for developing HUS following E. Coli
O157:H7 infection, and people >60-years old had the
highest mortality rate associated with E. Coli O157:H7
infection with or without HUS [9]. In the 2011 outbreak
of HUS associated with E. Coli O104:H4 in Germany, the
frequency of neurological symptoms was higher in adults
than in children which led to higher mortality rates. It was
found that deaths occurred acutely during initial
hospitalization mainly due to neurological damage with
symptoms consistent with cerebral edema and infarction,
sepsis, and electrolyte disturbances [2].
In addition to basic supportive care, multiple treat-
ment modalities ranging from antithrombotic agents,
PLEX, tissue-type plasminogen activator, oral Stx-
binding agent, and eculizumab have been studied in the
management of STEC-HUS. We will mainly focus on
PLEX and eculizumab therapy in this discussion as they
are the two most frequently studied therapies in HUS.
PLEX has been attempted as treatment for STEC-HUS.
The rationale behind PLEX use in STEC-HUS would be
to remove Shiga-like toxin and prothrombotic factors
caused by the toxin and inflammatory mediators, and
replace them with coagulation, tissue and complement
factors [6]. According to the 2010 guidelines of the
American Society for Apheresis, PLEX is listed as one of
the recommended treatments for STEC-HUS [10]. How-
ever, analysis of the 2011 E. Coli O104:H4-associated
HUS outbreak in Germany proposed that general sup-
portive care has the same clinical outcome as PLEX in
patients of all ages [2]. In our case presentation, we
learned that PLEX led to an initial improvement in
hemolysis and consumptive thrombocytopenia. PLEX























11 11.1 30 <3.0 2391 3.70 % 2.2 2.49 73 1.20 26.0 577
H0, ICU admission
at our center
7.6 6.4 57 NA 4576 6.20 % 1 6.8 112 1.43 35.8 412
H1, 1 day after
receiving
plasmapheresis
7.4 7.9 62 NA 992 NA 1 5.79 104 1.36 30.9 NA
H2, 2 days after
receiving
plasmapheresis
14.9 8.2 58 NA 1639 4.90 % 1.5 6.22 122 NA NA NA
H3, day stopped
plasmapheresis
16.8 8.9 33 NA 2489 4.10 % 2.1 4.78 117 1.40 38.8 148
Timeline of patient’s clinical course and hemolysis laboratory data changes with interventions. H0: hospital day 0; H1: hospital day 1; H2: hospital day 2; H3:
hospital day 3, NA: not available. BUN blood urea nitrogen, ICU intensive care unit, INR international normalized ratio, LDH lactate dehydrogenase, PTT partial
thromboplastin time, T. total, WBC white blood cell
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should be initiated early when MAHA is suspected as it
is often difficult to differentiate HUS from TTP and
there is a time lag to obtain the results for ADAMTS13
activity assay and stool studies [1].
Another therapy that has been studied in STEC-HUS
in children is eculizumab, a monoclonal antibody to C5
complement factor blocking complement activation.
Eculizumab has been shown to be an effective drug in
treatment of complement-mediated HUS (aHUS). There
have been case series which have demonstrated the
benefit of using eculizumab in children with STEC-HUS
and CNS involvement [11, 12]. On the contrary, other
studies reported that there was no benefit seen with use
of eculizumab in addition to standard medical care in
patients (both adults and children) affected in the 2011
outbreak of E. Coli O104:H4 [2, 4]. There is, however, a
lack of data supporting the use of eculizumab in the
older population with STEC-HUS. Further randomized
controlled trials are needed to identify whether, when,
and in which STEC-HUS cases eculizumab administra-
tion is beneficial. The most effective treatment in terms
of cost and safety was found to be general supportive
care with volume resuscitation, renal replacement ther-
apy, parenteral nutrition, and transfusion of blood prod-
ucts. Despite these therapeutic measures, STEC-HUS is
associated with a high risk of mortality especially in
older patients [2, 13].
Conclusions
This case demonstrates the importance of recognizing
STEC-HUS as an etiology of MAHA in older people. Cur-
rently, literature data support the view that supportive care
is the best approach for STEC-HUS. Conventional therap-
ies for other MAHA, such as PLEX and eculizumab, are
not shown to be effective in STEC-HUS. There is a dire
need to continue research and randomized controlled trials
to find better treatment options for STEC-HUS.
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